About Megafine
Megafine is a company based in Mumbai (India) founded in 1995 by Hasmukh Gandhi, Shailesh Sanghvi, and Ashok Jhaveri was acquired by Motilal Oswal in February 2025. The company has 536 employees as of July 31, 2024. Megafine operates in a competitive market with competitors including Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
- Headquarter Mumbai, India
- Employees 536 as on 31 Jul, 2024
- Founders Hasmukh Gandhi, Shailesh Sanghvi, Ashok Jhaveri
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$39.4 M (USD)7as on Mar 31, 2024
-
Net Profit
$4.22 M (USD)-8as on Mar 31, 2024
-
EBITDA
$7 M (USD)-9as on Mar 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
536
as on Jul 31, 2024
-
Acquired by
Motilal Oswal
(Feb 25, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Megafine
Detailed funding history for Megafine
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Megafine
Megafine has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Motilal Oswal Alternates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Motilal Oswal Alternates is engaged in alternative investment management.
|
Locked | Locked | Locked |
Investor details for Megafine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Megafine
Investment portfolio details for Megafine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Megafine
Detailed financials for Megafine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Megafine Comparisons
Peer comparison for Megafine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Megafine
Megafine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
Detailed competitors of Megafine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Megafine
Complete news archive for Megafine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Megafine
Megafine was founded in 1995.
Megafine is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
As of Jul 31, 2024, the latest employee count at Megafine is 536.
Annual revenue of Megafine is $39.4M as on Mar 31, 2024.
Megafine is engaged in manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and CDMO services for several global pharma companies. It has two multipurpose manufacturing sites, both successfully inspected by US-FDA one of them is also approved by EMEA, PMDA KFDA. It has 6 APIs under consideration, 9 API products under development, 5 APIs for veterinary use and 30 APIs for human use. It also has a portfolio of 32 intermediates. It offers small batch production to commercial batch size production services as part of its contract manufacturing services. It claims to have expertise in polymorphs and chiral products. Their CDMO services are mainly catered to novel niche products in therapeutic areas such as Anthelmintic, Cardiology, Urinary Incontinence, CNS and a few others.
Megafine's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Megafine has 1 investor. Key investors include Motilal Oswal Alternates.